Medline
Integrates medical-surgical products, third-party distribution, logistics, and clinical implementation support.
Something off on this page? Send us feedback.
Profile
Combines Medline Brand products in Front Line Care, Surgical Solutions, and Laboratory and Diagnostics with Supply Chain Solutions for third-party distribution and logistics. Sales are split roughly evenly between the two segments, while branded products contribute most segment earnings; global sourcing, delivery continuity, product quality, and Prime Vendor relationships shape the model.
Combines owned medical-surgical products with a broad third-party catalog through two segments: Medline Brand and Supply Chain Solutions. Front Line Care, Surgical Solutions, and Laboratory and Diagnostics span consumables, devices, and clinical product systems.
Serves hospitals and non-acute care sites through Prime Vendor contracts, distribution centers, an owned U.S. fleet, and clinical implementation support. Global manufacturing and sourcing feed a business whose sales are split roughly evenly between branded products and supply-chain services, while branded products contribute most segment earnings.
Execution rests on keeping products available, coordinating a wide supplier base, and delivering reliably across the network. Product quality and regulatory compliance, supplier and technology continuity, multi-year customer relationships, and principal-stockholder influence over board nominations shape the structure.
Company facts
Categories
Key statistics
Year to date −13.1% · Average volume (30d) 7.0M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 27, 2026 | BTIG | Reiterate | Buy | $50 | $55 |
| Aug 6, 2026 | Robert W. Baird | Target | $45 | $42 | |
| Aug 6, 2026 | Evercore ISI | Target | $55 | $39 | |
| Aug 6, 2026 | Stifel Nicolaus | Target | $55 | $45 | |
| Aug 6, 2026 | BMO Capital | Reiterate | Outperform | $45 | $47 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | $0.35 | $0.50 | +41.9% | $7.52B | $7.69B | +2.2% | −12.77% |
| May 6, 2026Q1 FY26 | $0.30 | $0.33 | +11.8% | $7.16B | $7.35B | +2.6% | −0.36% |
| Feb 25, 2026Q4 FY25 | $0.24 | $0.22 | −7.6% | $7.51B | $7.79B | +3.7% | +1.47% |
| Nov 4, 2025Q3 FY25 | — | $0.31 | — | — | $7.12B | — | — |
Financial highlights
| 8 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $6.64B | $6.89B | $7.12B | $7.79B | $7.35B | $7.69B | |
| Gross profit | $1.65B | $1.73B | $1.70B | $1.91B | $1.67B | $2.22B | |
| Operating income | $591.0M | $629.0M | $574.0M | $425.0M | $422.0M | $395.0M | |
| Net income | $322.0M | $333.0M | $322.0M | $180.0M | $129.0M | $60.0M | |
| Diluted EPS | $0.40 | $0.42 | $0.41 | $0.22 | $0.16 | $0.07 | |
| Gross margin | 24.8% | 25.1% | 23.9% | 24.6% | 22.6% | 28.8% | |
| Operating margin | 8.9% | 9.1% | 8.1% | 5.5% | 5.7% | 5.1% |
Fiscal years (4-quarter sums)FY25 $28.43B
Balance sheet, Jun 30, 2026Cash & short-term investments $2.68B · Total debt $12.64B · Total assets $39.35B · Shareholders' equity $11.57B
Dividends
No dividends on record.
Ownership
Shares outstanding 845.61M · Float 540.04M · 63.9% free float
Insiders — no current Form 4 position.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Mozart Aggregator II LP · 10 percent owner | 215.29M | Form 4 | Dec 22, 2025 | |
| Carlyle Group Inc. | 187.08M | 22.12% | 13F | Aug 7, 2026 |
| H&F Corporate Investors X, Ltd. | 70.87M | 8.38% | 13F | Aug 12, 2026 |
| FMR LLC | 46.96M | 5.55% | 13F | Aug 13, 2026 |
| Capital Research Global Investors | 39.96M | 4.73% | 13F | Aug 12, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 28, 2026 | BCP 8 Holdings Mozart Manager L.L.C. | 10 percent owner | −33,317,824 | $36.54 |
| Mar 10, 2026 | BCP 8 Holdings Mozart Manager L.L.C. | 10 percent owner | −27,852,986 | $40.51 |
| Mar 10, 2026 | Carlyle Group Inc. | 10 percent owner | −26,105,840 | $41.00 |
| Dec 18, 2025 | Mozart Aggregator II LP | 10 percent owner | −20,417,040 | $28.37 |
| Dec 18, 2025 | Carlyle Group Inc. | 10 percent owner | −19,136,333 | $29.00 |
Peers
- Cardinal Health
Integrated rival in med-surg distribution and branded supplies
- McKesson
National rival in med-surg distribution and non-acute logistics
- BD
Broad manufacturer rival in vascular access, diagnostics, and surgery
- Henry Schein
Office-based distributor with national and corporate-brand breadth
- Solventum
Product rival in wound care, infection prevention, and surgical support
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Medline | $35.03 | −0.70% | $29.83B | 41.0 | 23.9 | 1.0 | — |
| Cardinal Health | $232.64 | −0.84% | $54.93B | 32.4 | 18.7 | 0.2 | +5.8% |
| McKesson | $887.21 | −0.76% | $104.60B | 23.9 | 19.3 | 0.3 | +7.7% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| Henry Schein | $89.52 | +0.01% | $10.20B | 26.1 | 15.8 | 0.7 | +6.7% |
| Solventum | $90.50 | −0.68% | $15.78B | 11.1 | 13.5 | 1.9 | +2.2% |
| Median | 26.1 | 15.8 | 0.7 | +5.8% |